

MATTERS ARISING

Open Access



# Analgo-sedation in patients with acute respiratory failure on noninvasive ventilation: is it truly safe?

Manuel Alberto Guerrero-Gutiérrez<sup>1</sup> , Rafael Alfonso Reyes-Monge<sup>2</sup> , Ignacio Rodríguez-Guevara<sup>2\*</sup> , Diego Escarramán-Martínez<sup>3</sup> and Orlando Rubén Pérez-Nieto<sup>2</sup>

Dear Editor,

We read with interest the Delphi consensus on the management of analgo-sedation during noninvasive respiratory support [1] and believe that it is important to comment on the following considerations regarding sedation in patients receiving noninvasive ventilation (NIV) for acute respiratory failure (ARF).

Notably, the incidence of bradycardia is greater when dexmedetomidine is used during NIV ( $N=565$ ;  $RR$  1.90; 95%  $CI$  1.03–3.49;  $P=0.04$ ;  $I^2=0\%$ ) [2]. For this reason, the Delphi consensus authors recommend continuous monitoring of vital signs—a practice that, in resource-limited settings with minimal clinical staff and no telemetry, may carry significant risks with this drug. Additionally, other adverse effects that could compromise ventilation, such as vomiting, gastric aspiration, respiratory tract infection, and respiratory depression, have not been thoroughly evaluated [2].

The study by Yang et al. provides evidence on the potential benefits of sedation in reducing the need for

intubation and the risk of delirium, as well as on the advantage of dexmedetomidine over other sedatives, albeit with a higher incidence of bradycardia [2]. This additional discussion enriches our evaluation of the risks and benefits of sedation in NIV.

A recent large retrospective cohort study [3] involving patients with ARF due to obstructive lung disease, acute respiratory distress syndrome (ARDS), congestive heart failure, and mixed respiratory failure who received NIV ( $n=433,357$ ) revealed that 26.7% (95%  $CI$ , 26.3–27.0%) of these patients received sedation or analgesia. Among these patients, 50,589 (11.7%) received only opioids, 40,645 (9.4%) received only benzodiazepines, and 20,146 (4.6%) received both opioids and benzodiazepines. Additionally, 1573 patients (0.4%) were administered dexmedetomidine alone, and 2639 (0.6%) received dexmedetomidine in addition to opioids and/or benzodiazepines.

The risks of potential harm in NIV vary depending on the type of sedative or analgesic used (e.g. benzodiazepines) and the patient's clinical characteristics. Certain medications, such as benzodiazepines and opioids, are associated with a higher risk of NIV failure and mortality in patients with specific conditions, such as those at risk of developing ARDS or congestive heart failure.

The use of sedation was associated with increased odds of requiring intubation or mortality: opioids alone ( $OR$  1.23, 95%  $CI$  1.20–1.27), benzodiazepines alone ( $OR$  1.46, 95%  $CI$  1.41–1.51), opioids and benzodiazepines together ( $OR$  1.61, 95%  $CI$  1.55–1.68), dexmedetomidine alone ( $OR$  1.96, 95%  $CI$  1.71–2.24), and dexmedetomidine

\*Correspondence:

Ignacio Rodríguez-Guevara  
irodriguez20@alumnos.uaq.mx

<sup>1</sup> Department of Anesthesiology and Intensive Care Unit, Baja Medical Center, Tijuana, Baja California, Mexico

<sup>2</sup> Intensive Care Unit, Hospital General San Juan del Río, Queretaro, Mexico

<sup>3</sup> Department of Anesthesiology, Centro Médico Nacional "La Raza" IMSS, Mexico City, Mexico



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

combined with opioids and/or benzodiazepines (*OR* 1.91, 95% *CI* 1.72–2.13), all with  $p < 0.001$ . These results were consistent across multivariable models, which included available confounders, as well as an inverse probability weighting model. Despite the limitations of this study due to its observational nature, these findings suggest that the use of sedation and/or analgesia during NIV for ARF in patients with chronic obstructive pulmonary disease (COPD) and those at risk of acute respiratory distress syndrome (ARDS) (*OR* 1.54, 95% *CI* 1.49–1.58), congestive heart failure (*OR* 0.56, 95% *CI* 0.53–0.58), or mixed respiratory failure (*OR* 0.86, 95% *CI* 0.84–0.89) may carry potential harm by increasing both mortality risk and the likelihood of death and especially in those at risk of ARDS.

Paradoxically, despite real-world data indicating that the use of opioids during NIV for ARF is associated with a lower risk of intubation and death, their use has been declining in the USA over the past 10 years. Moreover, the use of dexmedetomidine has been increasing [2], despite safety alerts in Europe and Australia due to the increased mortality observed in intubated patients younger than 63.7 years compared with other sedatives [4].

In conclusion, these observations highlight the importance of critically evaluating sedation practices in patients with acute respiratory failure undergoing non-invasive ventilation. Further research is needed to ensure that sedative protocols align with patient safety and outcomes, particularly given the complex and potentially adverse effects associated with these interventions.

#### Abbreviations

NIV	Noninvasive ventilation
ARDS	Acute respiratory distress syndrome
ARF	Acute respiratory failure
RR	Relative risk
CI	Confidence interval
OR	Odds ratio

#### Acknowledgements

Not applicable.

#### Authors' contributions

MAGG, RARM, and IRG contributed equally to the writing of the manuscript. DEM and ORPN contributed to data interpretation and made substantive revisions. All authors read and approved the final manuscript.

#### Funding

None.

#### Data availability

No datasets were generated or analysed during the current study.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare no competing interests.

Received: 29 October 2024 Accepted: 15 December 2024

Published online: 21 December 2024

#### References

1. Spinazzola G, Spadaro S, Ferrone G et al (2024) Management of anal-gosedation during noninvasive respiratory support: an expert Delphi consensus document developed by the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). *J Anesth Analg Crit Care* 4:68. <https://doi.org/10.1186/s44158-024-00203-0>
2. Yang B, Gao L, Tong Z (2024) Sedation and analgesia strategies for non-invasive mechanical ventilation: a systematic review and meta-analysis. *Heart & lung: the journal of critical care* 63:42–50. <https://doi.org/10.1016/j.hrtlng.2023.09.005>
3. Dunbar PJ, Peterson R, McGrath M et al (2024) Analgesia and sedation use during noninvasive ventilation for acute respiratory failure. *Crit Care Med* 52(7):1043–1053. <https://doi.org/10.1097/CCM.0000000000006253>
4. Pérez-Nieto OR, Reyes-Monge RA, Rodríguez-Guevara I, Zamarrón-López EI, Meade-Aguilar JA (2023) Use of dexmedetomidine in critically ill patients: is it time to look to the actual evidence? *Crit Care* 27(1):332. <https://doi.org/10.1186/s13054-023-04618-z>

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.